Log In
Print
BCIQ
Print
Print this Print this
 

Herpes simplex virus type 2 (HSV-2) vaccine (Vaxfectin-formulated plasmid DNA HSV-2 vaccine)

  Manage Alerts
Collapse Summary General Information
Company Vical Inc.
DescriptionDNA vaccine encoding the HSV-2 glycoprotein D (gD2) antigen and tegument proteins UL46/UL47 formulated with the Vaxfectin lipid adjuvant
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I/II
Standard IndicationHerpes simplex virus (HSV)
Indication DetailsVaccinate against herpes simplex virus type 2 (HSV-2) infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today